Kumar PNS, Radhika MK, Suresh R, et al. - Researchers investigated female patients with schizophrenia receiving olanzapine or risperidone for the prevalence of sexual dysfunction. In addition, they sought to understand its correlation with other psychosocial variables. In this cross-sectional descriptive study, 57 female stabilized schizophrenia outpatients receiving risperidone (n = 28) or olanzapine (n = 29) were evaluated. Sexual dysfunction was reported in 93% of women receiving risperidone relative to 83% in the olanzapine group. Overall findings suggest that in the majority of female schizophrenia patients, sexual dysfunction is an important undetected problem. More sexual dysfunction was recorded in correlation with receiving risperidone. In the treatment of schizophrenia, sexual dysfunction is an understudied yet important consideration.